News
Posted on September 3, 2026
MUNICH — Remote exercise-based cardiac rehabilitation did not increase participation compared with center-based cardiac rehab in patients with heart attack, according to findings presented at the European Society of Cardiology Congress. However, patients with the option to use a remote exercise-based program had just as much improvement in physical capacity as those who had to use a center-based program only, according to the results of the Remote Exercise SWEDEHEART study. “Exercise as part of cardiac rehabilitation supports recovery and improves better long-term health after a heart attack.
Posted on September 3, 2026
The FDA added a boxed warning detailing the known risk for symptomatic hypophosphatemia associated with ferric carboxymaltose injection, according to an agency press release. The boxed warning recommends phosphate monitoring for patients at risk for hypophosphatemia and any patients who receive a repeat course of therapy within 3 months of the prior course. Generic ferric carboxymaltose injection products are also expected to update their labels to reflect the added boxed warning, according to the release. Ferric carboxymaltose injection (Injectafer, Daiichi Sankyo/American Regent), a
Posted on September 3, 2026
The internet went mainstream less than 40 years ago, yet it is hard to remember the world without it. Chadi Nabhan, MD, MBA, hematologist, medical oncologist, podcaster and author, believes the same will hold true for AI in the not-so-distant future. “There’s no way around it. AI is here to stay,” Nabhan told Healio. “Humans who are smart in using AI will advance better and faster in life and in career than humans who do not embrace AI.” The same holds true in healthcare. Clinicians and institutions that best utilize AI will likely have the greatest impact on patients. Barriers remain to
Posted on September 2, 2026
A continuing resolution awaiting President Donald Trump’s signature that would avert a government shutdown would also have implications for the federal grantmaking process. The U.S. House of Representatives passed H.R. 6500 on Sept. 1. If signed, the stopgap funding bill will temporarily block proposed changes to the federal grantmaking process. The vote was bipartisan, with 370 “yes” votes and 48 “no” votes. Fourteen members were recorded as not voting. As Healio previously reported, the Office of Management and Budget proposed what experts called “an unprecedented shift” in the way the
Posted on September 2, 2026
MUNICH — Starting 14-day ECG monitoring immediately after ED assessment for unexplained syncope did not result in fewer patient-reported recurrent episodes at 1 year compared with standard care, according to results of the ASPIRED trial. However, early use of a wearable patch for 14 days more than doubled detection of serious arrhythmias and led to more patients receiving treatment, researchers reported at the European Society of Cardiology Congress. The ASPIRED trial, simultaneously published in The New England Journal of Medicine, included 2,234 patients (mean age, 58.3 years; 52.1% men; 89%
Posted on September 2, 2026
Adults with both obstructive sleep apnea and insomnia vs. only obstructive sleep apnea had larger decreases in 24-hour, daytime and nocturnal systolic blood pressure following 4 weeks of CPAP, according to data published in CHEST. “These findings underscore the potential for a more personalized management strategy for [blood pressure] management in patients with OSA, where the presence of comorbid insomnia may signal a subgroup with a distinct and favorable hemodynamic response to CPAP therapy,” Shuang Li, MD, of Capital Medical University in China, and colleagues wrote. In a prospective cohort
Posted on September 2, 2026
Patients with systemic lupus erythematosus and sustained low hydroxychloroquine blood levels may be at significantly increased risk for atherosclerotic cardiovascular disease, according to data published in Arthritis Care & Research. “Hydroxychloroquine (HCQ) is the cornerstone of SLE management because it reduces disease activity, prevents flares, limits organ damage accrual and has been associated with cardiovascular protection,” Shivani Garg, MD, PhD, director of the Yale Lupus Program, told Healio. “This study provides hypothesis-generating evidence that optimizing
Posted on September 1, 2026
Adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 1 year with tirzepatide plus ixekizumab vs. ixekizumab monotherapy, according to a Lilly press release. One-year data from the phase 3b, randomized, double-blind, open-label TOGETHER-PsO and TOGETHER-PsA trials build on the previously reported 36-week findings that showed marked improvement in psoriatic disease outcomes and body weight among people who received combination therapy with ixekizumab (Taltz, Lilly), an IL-17A inhibitor, and tirzepatide (Zepbound,
Posted on September 1, 2026
MUNICH — In patients with atrial fibrillation, catheter ablation did not improve quality of life at 6 months compared with a sham procedure, according to the PVI-SHAM-AF trial presented at the European Society of Cardiology Congress. However, fewer patients in the catheter ablation group had recurrent AF at 6 months compared with the sham group. The results differ from the SHAM-PVI trial presented at the ESC Congress in 2024 and published in JAMA, which found that catheter ablation improved quality of life compared with a sham procedure. The PVI-SHAM-AF trial, simultaneously published in The
Posted on September 1, 2026
Click here to read the Healio Exclusive, “Experience builds confidence when it comes to speaking at meetings.” I am often asked by residents, fellows and younger ophthalmologists to share the pathway to becoming a key opinion leader in ophthalmology and a regular invited speaker at educational meetings. In the following paragraphs, I will share a few thoughts gained from my personal journey as a lecturer and a frequent organizer of educational programs today. Remember, there is no elevator to success or excellence as a key opinion leader (KOL) or speaker — you must take the stairs. The first
Posted on August 31, 2026
MUNICH — In patients with cardiac arrest but no ST elevation, immediate coronary angiography did not improve survival or neurological outcomes compared with deferred angiography, according to results of the DISCO study. “Immediate coronary angiography of the cardiac arrest does not improve survival or neurological outcomes. The case is closed,” Sten Rubertsson, MD, PhD, professor of anesthesiology and intensive care medicine at Uppsala University in Sweden, said during a press conference at the European Society of Cardiology Congress. The DISCO study was the largest to examine whether immediate
Posted on August 31, 2026
Nearly 30% of adults with an elevated BMI in the U.S. and more than 97% of those with a high BMI in Japan did not receive a diagnosis for obesity, according to findings from the CALOR study published in Obesity. Deborah B. Horn, DO, MPH, DABOM, MFOMA, medical director at the University of Texas Center for Obesity Medicine and Metabolic Performance and clinical assistant professor in the department of surgery at University of Texas McGovern Medical School in Houston, and colleagues wrote that the shift in recognizing obesity as a chronic disease makes it crucial to understand the prevalence of
Posted on August 31, 2026
Click here to read the At Issue to this Healio Exclusive. Take a look at the Healio | OSN calendar page, and you will find more than three dozen meetings, symposia and summits that make up a year of ophthalmology gatherings. Whether they are one-room, single-day conferences, such as Clinical Trials at the Summit, or they take up full convention centers, such as the American Academy of Ophthalmology annual meeting, they all give physicians a chance to stand in front of their peers to present research, discuss hot topics and celebrate their profession. Speaking at these conferences is a shared
Posted on August 31, 2026
MUNICH — Adults with atrial fibrillation participating in a yearlong high-intensity exercise program spent nearly 50% less time in AF and were less likely to be hospitalized for any cause compared with usual care, researchers reported. “Exercise is now part of the guideline recommendations, but it is still underused,” Bjarne Martens Nes, PhD, a researcher with the Cardiac Exercise Research Group at Norwegian University of Science and Technology, said during a press conference at the European Society of Cardiology Congress. “We also know that many patients and doctors remain unsure of whether
Posted on August 31, 2026
MUNICH — In patients with severe hypertriglyceridemia, plozasiran was well-tolerated, reduced triglycerides by up to 81% and prevented acute pancreatitis events compared with placebo, a speaker reported. “Severe hypertriglyceridemia is probably one of the largest gaps in the management of lipid disorders. Above 5 mmol/L is a gateway for all sorts of conditions that preventative cardiologists [and] diabetologists have difficulty accessing and treating because the treatments are not very effective,” Gerald F. Watts, DSc, MD, PhD, FRCP, FRACP, FCSANZ, Winthrop Professor of Cardiometabolic
Posted on August 30, 2026
MUNICH — A strategy of transcatheter tricuspid valve repair on top of optimal medical therapy was superior to medical therapy alone for patients with symptomatic severe tricuspid regurgitation and heart failure, according to new data. In addition to improvements in quality of life previously seen in tricuspid valve repair trials, the interventional was associated with meaningful reductions in all-cause death and HF hospitalization — benefits that emerged early and were sustained up to 3 years, researchers reported at the European Society of Cardiology Congress. “For most of
Posted on August 30, 2026
MUNICH — A digital strategy involving an emailed letter inviting patients with heart failure to be evaluated by a specialist for SGLT2 inhibitor therapy dramatically increased SGLT2 inhibitor prescriptions, researchers reported. For the EMAIL-HF registry-based randomized trial, presented at the European Society of Cardiology Congress, researchers identified all patients with HF in the Capital Region of Denmark and the municipality of Roskilde who were not receiving an SGLT2 inhibitor and randomly assigned them to the digital strategy or the usual care. Patients in the digital strategy
Posted on August 30, 2026
MUNICH — More than half of healthy adults in Denmark and Spain had silent atherosclerosis detected across three vascular territories via imaging, including nearly 9% of men and 7% of women aged 18 to 29 years, according to new data. “More than half of the study population of 16,808 healthy individuals aged 18 to 70 years had atherosclerosis,” Henning Bundgaard, MD, DMSc, from the department of cardiology, the Heart Center, Rigshospitalet, Copenhagen University Hospital, Denmark, said during a press conference at the European Society of Cardiology Congress. “This is a disease that may lead to
Posted on August 30, 2026
MUNICH — In patients at high ischemic risk implanted with a drug-eluting stent who had 12 months of dual antiplatelet therapy, switching to clopidogrel monotherapy increased ischemic events but reduced bleeding events, a speaker reported. Byeong-Keuk Kim, MD, PhD, professor in the department of internal medicine at Yonsei University College of Medicine in Seoul, South Korea, said during a presentation at the European Society of Cardiology Congress that these data may caution against routine antiplatelet therapy deescalation in patients who may be at elevated ischemic risk. “Current
Posted on August 29, 2026
MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker reported. The LIBREXIA trial evaluating the small-molecule factor XIa inhibitor milvexian (Bristol Myers Squibb/Johnson & Johnson) in patients at risk for recurrent ischemic events after an ACS event was halted early for futility, according to results presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine. “Milvexin is an oral factor XIa
Stay updated
Sign up to receive news and updates on our iniciatives, content and events.